


Dosing Guidelines for GLYCOPYRONIUM

AGE GROUP	INDICATION	ROUTE	DOSE	REMARKS
Neonatal	Endotracheal intubation, nonemergent	IV	4 to 10 mcg/kg as a single dose	(Acceptable, but not preferred vagolytic). A small study of 20 neonates used 3 to 5 mcg/kg as a single dose prior to intubation.
Pediatric	Chronic drooling Children ≥3 years and Adolescents ≤16 years:	Oral	20 mcg/kg/dose 3 times daily	Titrate in increments of 20 mcg/kg/dose every 5 to 7 days as tolerated to response up to a maximum dose of 100 mcg/kg/dose 3 times daily; not to exceed 1,500 to 3,000 mcg/dose. Patients <3 years: Safety and efficacy not established.
	Control of respiratory secretions, palliative care	IV, IM	4 to 10 mcg/kg/dose every 4 to 8 hours	
	Control of respiratory secretions, palliative care	Oral	40 to 100 mcg/kg/dose every 4 to 8 hours	
	Reduction of secretions (preoperative) Infants and Children ≤2 years:	IM	4 to 9 mcg/kg/dose 30 to 60 minutes before procedure	Preoperative: 30-60 min before surgery Intraoperative: May repeat q2-3min; not to exceed 0.1 mg
	Reduction of secretions (preoperative) Children >2 years and Adolescents:	IM	4 mcg/kg/dose 30 to 60 minutes before procedure	
	Reversal of bradycardia, vagal reflexes (intraoperative) Infants, Children, and Adolescents	IV	4 mcg/kg/dose	(Maximum dose: 100 mcg/dose) at 2 to 3 minute intervals
	Reversal of muscarinic effects of cholinergic agents Infants, Children, and Adolescents	IV	0.2 mg for each 1 mg of neostigmine or 5 mg of pyridostigmine administered	

AGE GROUP	INDICATION	ROUTE	DOSE	REMARKS
Adult	Primary focal hyperhidrosis	Oral	1 to 2 mg once or twice daily	Titrate per response and tolerability; doses up to 6 to 8 mg per day in 2 or 3 divided doses have been used in some patients.
	Droling	Oral	0.1 mg/kg twice or every 8 hours	Not to exceed 8 mg/day.
	Reduction of secretions (preoperative)	IM	4 mcg/kg 30 to 60 minutes	before anesthesia or when the preanesthetic opioid and/or sedative are administered
	Reduction of secretions at end of life (death rattle)	IV, SUBQ	0.2 mg every 4 to 8 hours as needed	Do not exceed 4 doses/day or 0.4 mg every 6 hours.
	Reversal of bradycardia, vagal reflexes (intraoperative)	IV	0.1 mg as a single dose.	Repeat as needed at 2- to 3-minute intervals.
	Reversal of muscarinic effects of cholinergic agents:	IV	0.2 mg for each 1 mg of neostigmine or 5 mg of pyridostigmine administered	
	Adjunct to Treatment of Peptic Ulcer	Oral	1.7 mg twice or every 8 hours	Not to exceed 6.8 mg/day.
	Chronic obstructive pulmonary disease, maintenance: Nebulization solution (25 mcg/1 mL vial)	Nebulization	25 mcg inhaled twice daily	
	Chronic obstructive pulmonary disease, maintenance: Dry powder inhaler (50 mcg/capsule)	Dry powder inhaler	50 mcg inhaled once daily.	



Kidney

Impairment

No dosage changes necessary.



Liver

Impairment

No dosage changes necessary.

REFERENCES

- Bajaj V, Langtry JA. Use of oral glycopyrronium bromide in hyperhidrosis. *Br J Dermatol*. 2007;157(1):118-121. doi:10.1111/j.1365-2133.2007.07884.x[[PubMed 17459043](#)]
- Blinderman CD, Billings JA. Comfort care for patients dying in the hospital. *N Engl J Med*. 2015;373(26):2549-2561. doi:10.1056/NEJMra1411746[[PubMed 26699170](#)]
- Kintzel PE, Chase SL, Thomas W, Vancamp DM, Clements EA. Anticholinergic medications for managing noisy respirations in adult hospice patients. *Am J Health Syst Pharm*. 2009;66(5):458-464. doi:10.2146/ajhp080194[[PubMed 19233993](#)]
- Likar R, Rupacher E, Kager H, Molnar M, Pipam W, Sittl R. Efficacy of glycopyrronium bromide and scopolamine hydrobromide in patients with death rattle: a randomized controlled study [in German]. *Wien Klin Wochenschr*. 2008;120(21-22):679-683. doi:10.1007/s00508-008-1094-2[[PubMed 19116709](#)]
- Prommer E. Anticholinergics in palliative medicine: an update. *Am J Hosp Palliat Care*. 2013;30(5):490-498. doi:10.1177/1049909112459366[[PubMed 22964342](#)]
- Solish N, Bertucci V, Dansereau A, et al; Canadian Hyperhidrosis Advisory Committee. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. *Dermatol Surg*. 2007;33(8):908-923. doi:10.1111/j.1524-4725.2007.33192.x[[PubMed 17661933](#)]
- Walling HW. Systemic therapy for primary hyperhidrosis: a retrospective study of 59 patients treated with glycopyrrolate or clonidine. *J Am Acad Dermatol*. 2012;66(3):387-392. doi:10.1016/j.jaad.2011.01.023[[PubMed 21820204](#)]